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Notch Signaling in Cancer
Abstract
Notch signaling plays a key role in the normal development of many tissues and cell types, through diverse
effects on differentiation, survival, and/or proliferation that are highly dependent on signal strength and
cellular context. Because perturbations in the regulation of differentiation, survival, and/or proliferation
underlie malignant transformation, pathophysiologic Notch signals potentially contribute to cancer
development in several different ways.
Notch signaling was first linked to tumorigenesis through identification of a recurrent t(7;9)(q34;q34.3)
chromosomal translocation involving the human Notch 1 gene that is found in a small subset of human pre-T-
cell acute lymphoblastic leukemias (T-ALL).1 Since this discovery, aberrant Notch signaling has been
suggested to be involved in a wide variety of human neoplasms. In this review, we will focus on recent studies
linking aberrant Notch signaling with cancer. First, we discuss various mechanisms through which Notch
signaling may influence cellular transformation. Then, we critically review literature pertaining to the role of
Notch signaling in several cancers, and discuss possible therapeutic targets in the Notch pathway.
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ABSTRACT 
Notch signaling plays a key role in the normal development of many tissues and cell
types, through diverse effects on differentiation, survival, and/or proliferation that are
highly dependent on signal strength and cellular context. Because perturbations in the
regulation of differentiation, survival, and/or proliferation underlie malignant transfor-
mation, pathophysiologic Notch signals potentially contribute to cancer development in
several different ways.
Notch signaling was first linked to tumorigenesis through identification of a recurrent
t(7;9)(q34;q34.3) chromosomal translocation involving the human Notch1 gene that is
found in a small subset of human pre-T-cell acute lymphoblastic leukemias (T-ALL).1 Since
this discovery, aberrant Notch signaling has been suggested to be involved in a wide
variety of human neoplasms. In this review, we will focus on recent studies linking 
aberrant Notch signaling with cancer. First, we discuss various mechanisms through
which Notch signaling may influence cellular transformation. Then, we critically review
literature pertaining to the role of Notch signaling in several cancers, and discuss possible
therapeutic targets in the Notch pathway.
NOTCH SIGNALING 
Notch genes, named after the notched wing phenotype of mutant Drosophila,2 encode
highly conserved cell surface receptors. The Notch signaling pathway, in which almost all
elements are conserved from Drosophila to humans, consists of Notch receptors, ligands,
negative and positive modifiers, and transcription factors. In mammals, these functional
classes each have multiple members, and the interplay between these molecules is not yet
fully understood. Studies in Drosophila suggest, however, that Notch receptors and ligands
generally influence lineage specification through two mechanisms: lateral inhibition and
lateral induction (for review, see ref. 3). In lateral inhibition, a cluster of equivalent 
precursor cells evolves into two distinct classes (Notchhi and Notchlo) through an assortment
of negative feedback loops that create cell-to-cell variation in Notch signaling tone. A 
classic example is Drosophila sensory organ development, during which equivalent 
precursor cells expressing both ligand and receptor become either epithelial cells (Notchhi)
or sensory organ precursor cells (Notchlo) through amplification of small stochastic differences
in the initial levels of Notch signaling. In contrast, inductive signaling involves two
non-equivalent cell types that express either the receptor or the ligand. The receptor-
expressing cell responds to ligand stimulation, triggering a cell fate decision dependent on
access to the appropriate ligand(s). During the development of complex tissues, both
mechanisms may be operative. 
Notch Structure and Pathway. The four mammalian Notch receptors (Notch1–4) are
large, Type I transmembrane proteins comprised of multiple structural motifs (reviewed in
ref. 4) (Fig. 1). In route to the cell surface, the Notch receptor is proteolytically cleaved by
furin-like convertases in the trans-Golgi network, giving rise to the two subunits of the
mature receptor. The extracellular Notch (ECN) subunit consists largely of a ligand-binding
domain composed of tandem epidermal growth factor (EGF)-like repeats, and three
LIN12/Notch repeats that appear to restrain inappropriate, ligand-independent receptor
activation. The transmembrane Notch subunit (NTM) includes a short extracellular
domain, a single transmembrane domain, and a large intracellular domain comprised of a
RAM sequence, seven iterated cdc10/ankyrin-like repeats, two nuclear localization signals
(NLS), and a C-terminal PEST sequence. In addition, mammalian Notch 1, 2 and 3 
contain cytokine response (NCR) regions, and Notch 1 and 2 have C-terminal transcriptional
activation domains (TAD). 
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Assembly of the Notch enhanceosome results in transcription of
a variety of downstream targets. In many cells, Notch activates
expression of a group of basic-helix-loop-helix-orange (bHLH-O)
proteins, including several members of the mammalian
Hairy/Enhancer of Split (HES) genes and Hairy-related genes
(HRT) (for review, see ref. 13). These proteins repress gene expression
through recruitment of transcriptional corepressors of the groucho/
TLE family.14 The bHLH-O proteins also heterodimerize with
bHLH activators, which may constitute a second level of bHLH
inhibition. Other putative direct targets of Notch transcriptional
activation include the C. elegans MAPK phosphatase LIP1, which
regulates early events in vulval development;15 pre-T alpha,16 an
important regulator of T cell development; and cell-cycle regulators
such as cyclinD1 and p21WAF1-CIP1.17-19 These diverse targets illus-
trate that the transcriptional consequences of Notch signaling vary
depending on cell type and stage of differentiation, despite the
stereotyped nature of the central Notch/CSL signaling axis. Major
challenges in Notch biology are to identify the relevant targets of
Notch signaling in particular contexts, and to understand the basis
for divergent effects in the different contexts.
Notch signaling is subject to regulation at several levels. Notch
activation by ligands of the Jagged/Serrate familiy is inhibited by
glycosyl transferases of the Fringe family, which appear to modify the
extracellular domains of Notch receptors,20-24 whereas activation by
Delta ligands is enhanced by Neuralized, an E3 ligase (for review, see
ref. 25). Two ligand-dependent cleavages are performed successively
by ADAM family metalloproteases, which cleave the extracellular
domain of NTM, and the presenilin protease complex, which is
Notch signaling begins with ligand binding, which triggers two
successive proteolytic cleavages that release the active intracellular
domain of Notch (ICN) from the cell membrane (Fig. 2) (for review,
see ref. 5). ICN translocates to the nucleus, where it interacts with
transcriptional regulatory factors. The only characterized transcription
factor that binds ICN is CSL (CBF1/RBP-Jk, Suppressor of
Hairless, LAG-1). In the absence of ICN, CSL is as a transcriptional
repressor, associated with histone deacetylases and corepressors.6
Binding of ICN to CSL displaces corepressor complexes, and
recruits coactivators, leading to transcription from promoters 
containing CSL-binding elements. The Notch transcriptional 
activation complex or enhanceosome appears to be a large
(~1.5Mda) protein complex, of which ICN, CSL, and Master-
mind-like (MAML) polypeptides are key components.7 In vitro
reconstitution of transcription from CSL-dependent promoter 
elements on chromatin templates requires ICN, CSL and MAML1.8
MAMLs are glutamine-rich nuclear proteins that binds to Notch
ankyrin repeats, form stable ternary complexes with ICN and CSL
on DNA, and recruit CBP/p300, a histone acetylase.8 In cells, intact
MAML1 amplifies activation of CSL reporter genes dramatically,
whereas truncated forms of MAML1 behave as dominant negative
inhibitors of ICN-dependent CSL activation.9 Based on its size,7 the
stable enhanceosome complex must contain other unknown 
components. Another potential component is SKIP, which interacts
with the CSL-ICN corepressor complex and assists in its conversion
to an activator complex.10 Lastly, several reports are consistent with
the existence of CSL-independent signaling pathways, the details of
which are not yet determined.11,12 
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Figure 1. Human Notch receptors. Diagrammatic representations of the 4 known human Notch receptors (hNotch). The full-length proteins are expressed
on the cell surface as heterodimers composed of non-covalently associated extracellular and transmembrane Notch subunits. All Notch receptors contain
epidermal growth factor like repeats (EGFR), Lin12 Notch repeats (LNR), a RAM23 domain (RAM), Ankyrin repeats (ANK), PEST (P) sequences, and two
nuclear localization signals (NLS1, NLS2). The highest degree of homology between Notch receptors is in the ankyrin repeats, whereas the C-terminal
sequences show the greatest degree of divergence. Human Notch1-3 contain Cytokine Response (NCR) sequences immediately C-terminal of the ankyrin
repeats that regulate functional activity. hNotch1 and hNotch2 also contain strong and weak, respectively, transcriptional activation domains (TAD) in
between the NCR and PEST sequences.
The first T cells to appear in the bone marrow of mice reconsti-
tuted with ICN1-expressing stem cells resemble small, non-cycling
DP thymocytes. This indicates that outgrowth of highly proliferative
ICN-associated T-ALL requires secondary events, which have yet to
be identified in sporadic human T-ALLs and corresponding murine
models. Within the hematopoietic compartment, ICN1 has a striking
oncotropicity for T cell progenitors. Stem cells bearing deficiencies
of recombinase activating genes (RAG), which prevent the development
of normal CD4+CD8+ T cells, fail to form lymphoid malignancies
in reconstituted mice even if followed for more than a year.42 The
malignant phenotype is recreated in the RAG-/- background by the
addition of a TCRβ transgene, which permits maturation to the
CD4+CD8+ stage.42 Whether a functional TCRβ merely allows the
development of cells (the DP T cell) susceptible to ICN1 transfor-
mation, or actively participates in propagation of transforming signals
(such as through activation of MAPK) (for review, see refs. 46, 47)
remains to be ascertained. 
NOTCH AND CANCER 
responsible for clevage within transmembrane domain to create
active ICN (for review, see ref. 26). Within the cell, Notch signaling
is modified by a number of additional factors, including: Numb, a
cytoplasmic negative regulatory protein;27 Deltex, a predominantly
cytoplasmic protein that enhances Notch signaling in some 
contexts28,29 and inhibits it in others;30,31 SEL-10, an F-box protein
that promotes ICN turnover;32 and unidentified kinases that mark
ICN for degradation. Precise regulatory mechanisms are still emerging,
but the multiplicity of regulators suggests that fine-tuning of Notch
signals is of great biological significance. 
POTENTIAL MECHANISMS OF NOTCH IN CANCER 
Selecting from the growing literature on Notch and cancer, we
present here several relatively well-characterized examples of how
Notch participates in tumor development. First, we discuss the role
of constitutive activation of the Notch pathway in lymphoblastic
leukemia/lymphomas, other lymphoproliferative disorders, and
mammary gland tumors. We then contrast these findings with
results suggesting certain epithelial tumors arise through downregu-
lation of Notch signaling. The ability of Notch to potentially function
as an oncoprotein or a tumor suppressor in certain contexts is
unusual, but perhaps not surprising given its diverse roles during
normal development. 
Notch and Lymphoid Neoplasms. In the late 1980s, Jeff Sklar’s
group identified a recurrent translocation t(7;9) associated with a
small subset of T-ALLs.1,33 Analysis of these tumors showed that the
breakpoints on chromosome 9 fell within the NOTCH1 locus and
resulted in the juxtaposition of the T-cell receptor-β promoter/
enhancer region with the 3´ end of NOTCH1 on the derivative
chromosome 9.1 As TCRβ is continuously expressed in T cells, the
translocation caused dysregulated expression of a series of tumor-
specific 5´-deleted NOTCH1 mRNA transcripts (reviewed in ref.
34) (Fig. 3). All known t(7;9) breakpoints fall within a single intron
within the coding sequence EGF repeat 34 of Notch1. However,
biochemical studies have shown that the t(7;9)-specific transcripts
encode a predominantly nuclear ICN1-like molecule.35 A murine
bone marrow transplant model has confirmed the central role of
Notch1 in the pathogenesis of this tumor, as mice reconstituted with
bone marrow stem cells expressing constitutively active Notch1 
rapidly and uniformly develop T-ALL.36,37 One primary effect 
of constitutive Notch1 activation is the maturation arrest of T 
lymphoblasts at the CD4+CD8+ double positive (DP) stage, an
event that correlates with subsequent development of T-ALL (for a
review, see ref. 34).
Insights into possible mechanisms relevant to the pathogenesis of
Notch1-related T-ALL have come from studies looking at the role 
of Notch signaling in normal T cell development. Both Notch1
expression and activity appear to be triphasic during normal thymo-
cyte development (reviewed in ref. 4). Levels are highest at the earliest
stages of T cell development (CD4-CD8- (DN) cells), low in
CD4+CD8+ DP cells, and intermediate in both the CD4+ and
CD8+ single positive (SP) cells.38,39 A variety of gain and loss 
of function studies have shown that Notch1 signaling through CSL
is required for T cell commitment from a common lymphoid 
progenitor.40-44 Although constitutive Notch1 activity drives 
common lymphoid progenitors to the T lineage, failure to downreg-
ulate Notch signaling at the double positive (DP) stage prevents 
further maturation.45 Thus, one potential Notch1 transforming
activity is to allow survival of DP cells otherwise destined for 
apoptosis, and/or to cause maturation arrest at the DP stage. 
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Figure 2. Ligand-induced Notch signaling pathways. Binding of Notch
receptors to ligands of the Jagged and Delta-like ligand (Dll) families result
in successive cleavages, first in the extracellular domain by ADAM-type 
proteases, and then in the transmembrane domain by presenilin-dependent
proteases, which release ICN and permit its translocation to the nucleus. The
ability of Jagged/Serrate ligands to activate Notch is antagonized by Fringe
(FNG) glycosylases, which modify Notch extracellular domains. In the nucleus,
ICN activates target gene expression by binding the transcription factor CSL,
displacing corepressors (CoR), and recruiting coactivators (CoA), including
Mastermind-like polypeptides (MAML). Poorly characterized CSL-independent
pathways also exist. Notch signals are negatively regulated by the 
cytoplasmic protein, Numb. See the text for additional details. 
Leukemia Virus (MuLV) and Feline Leukemia Virus (FeLV) causing
gain of function mutations of Notch1 and Notch2, respectively, have
been found in T-ALL.48,49 In both instances, a subset of the insertions
cause Notch rearrangements similar to those observed in human
T-ALLs associated with the t(7;9) (Fig. 3). A high prevalence of
Notch1 insertional mutagenesis was detected in early onset T-ALLs
arising after MuLV infection of c-myc or E2A-PBX transgenic
mice.50,51 Interestingly, two types of proviral insertions were
observed. The first occurred just 5´ of the Notch1 transmembrane
region coding sequence, presumably giving rise to a gain-of-function
truncation mutant similar to that produced by the t(7;9). The 
second type was found clustered at the 3´ end of the Notch1 gene
From a therapeutic vantage, it is important to consider whether
signaling is required for tumor maintenance once full-blown
Notch1-related T-ALL has been established. Recent results from the
Aster lab show that inhibition of Notch signaling in several
Notch-transformed T cell lines results in a G1/G0 cell cycle arrest
followed by apoptosis (Weng A et al., submitted). These data provide
support for therapeutic targeting of the Notch pathway in T-ALL.
The phenotype associated with withdrawal of signals also suggests
that Notch contributes to T cell transformation by influencing 
proliferation and survival, rather than merely blocking differentiation.
Genetic alterations of Notch have also been identified in T cell
tumors in other species. Proviral insertions of Moloney Murine
NOTCH AND CANCER 
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Figure 3. Schematic representation of translocations and proviral insertions involving Notch receptor genes. T-ALL. The t(7;9) translocation involving the
human Notch1 gene and the TCRβ promoter/enhancer region is shown. The translocation results in a series of tumor-specific 5’-deleted Notch1 mRNA 
transcripts. All known breakpoints fall within a single intron in the coding sequence for the EGF repeat 34 of Notch1. MuLV-Notch1. Proviral insertions occur
just 5’ of the Notch1 transmembrane region coding sequence and result in similar 5’-deleted transcripts as produced by the t(7;9). See text for the description
of a less well characterized second type of insertion, which is found clustered at the 3’ end of the Notch1 gene just 5’ of the PEST coding sequence.
FeLV-Notch2. A FeLV excision of a 3’ portion of the Notch2 gene is depicted. The transduced portion of Notch2 spans the coding sequences from the trans-
membrane domain to just C-terminal of the ankyrin repeat region. MMTV-Notch4. Proviral insertion occurs within a short stretch of DNA containing exons
21 and 22 of Notch4, just downstream of the three LIN12 repeats and upstream of the transmembrane sequence. 
NOTCH AND CANCER 
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just 5´ of the PEST coding sequence. The mechanism of transfor-
mation in this second type of proviral insertion has not yet been well
characterized, but similar mutations in flies produce gain-of-function
phenotypes. In the case of FeLV, a FeLV strain that produced T-ALLs
after a shorter latency period than wild type FeLV was found to have
recombined with a 3´ portion of the Notch2 gene.49 The transduced
portion of Notch2 spanned the coding sequences from the trans-
membrane domain to just C-terminal of the ankyrin repeat region
(Fig. 3). The retroviral LTR drives expression of a truncated consti-
tutively nuclear form of Notch2 in transfected cells, suggesting it
acts as a gain-of-function mutant. Transgenes encoding activated
forms of Notch3 also cause T-ALL in mice.52 Similar to Notch1,
these tumors are dependent on expression of a functional pre-T cell
receptor.53
To date, translocations or mutations involving Notch2 or Notch3
have not been identified in human T-ALL. It could be argued that
this is due to differences in the intrinsic transforming potential of
ICN1-3, as ICN1 is a more potent activator of CSL-dependent 
promoter elements than ICN2 or ICN3,54 but the ability of ICN2
and ICN3 to cause T-ALL in other mammals makes this doubtful.
Of note, many Notch gain-of-function alleles identified in fly and
worm genetic screens have proved to be due to point mutations in
Notch receptors. Until thorough searches have been conducted for
analogous mutations in Notch1-3 in sporadic human T-ALLs, the
prevalence of Notch gain-of-function mutations will remain
unknown. It is also notable that enforced expression of the Notch
ligand Dll4 in hematopoietic stem cells induces T-ALL.55 Thus, 
dysregulation of Notch pathway components other than the receptors
could contribute to leukemogenesis in man. 
Mutation or chromosomal rearrangements of Notch receptor
genes have not yet been identified outside of T-ALL, but evidence in
some other lymphoid tumors points to the possibility of dysregulated
Notch signaling. The expression of Notch1 was recently studied by
immunohistochemistry in various subsets of human lymphomas.56
Strong staining for Notch1 was consistently found in Hodgkin’s
lymphoma (HL), a tumor derived from germinal center B cells, and
anaplastic large cell lymphoma (ALCL), a tumor of cytotoxic T cells.
Staining was weak in Burkitt’s lymphoma, diffuse large B cell 
lymphoma, and weak or absent in other entities. High expression of
Notch1 and Notch2 was also observed in HL and ALCL cell lines.
When cocultured with feeder cell lines bearing the ligand Jagged1,
both tumor cell lines upregulated the Notch target gene HES-1 and
exhibited an increased growth fraction and decreased apoptosis.
Immuno-histochemistry showed Jagged1 was present in primary
tumors, both on HL and ALCL tumor cells and surrounding reactive
cell types, suggesting that Notch signaling could be triggered in vivo
through cell-cell interactions. Much additional work is needed to
determine whether Notch signaling is necessary for HL and ALCL
growth and survival in vitro and in vivo. For example, mouse models
of ALK-associated lymphoma would be helpful in further evaluating
the role of Notch signaling in ALCL. 
Circumstantial evidence also suggests a role for Notch2 in B-cell
chronic lymphocytic leukemia (CLL).57 High surface expression of
the transmembrane glycoprotein CD23 is characteristic of CLL
cells. While investigating CD23 expression, Hubmann et al. identified
putative CSL-binding sites within the CD23 promoter, and showed
Notch2 to be present in a multiprotein nuclear complex that binds
the CD23 promoter. An anti-apoptotic role for the Notch pathway
in CLL cells has been proposed,57 but additional experimentation is
needed to test this rigorously. 
Recent evidence suggests Notch signaling within the murine
naïve B cell compartment is necessary for specification of splenic
marginal zone fate, but not splenic germinal center B cell fate.58 Of
interest, based on expression profiling studies, human B-cell CLL
cells most closely resemble normal marginal zone B cells,59 offering
a possible link between this form of B cell neoplasia and a physio-
logic role for Notch signals in the peripheral B cell compartment.
Conversely, Notch signaling promotes growth arrest and/or apoptosis
of some avian and murine B cell lines60,61 (He Y, Pear WS, in prepa-
ration). Thus, Notch signaling might also inhibit the growth and
survival of certain lymphoid malignancies. 
Notch and Mammary Tumors. An important role for Notch
signaling in murine mammary cancer has been well documented.
Mouse Mammary Tumor Virus (MMTV) is a retrovirus that causes
mammary tumors through insertional mutagenesis of the mouse
genome.62 One such recurrent integration site, int-3, lies within 
the Notch4 gene.63-65 Proviral insertion commonly occurs within a
short stretch of DNA containing exons 21 and 22 of Notch4, just
downstream of the three LIN12 repeats and upstream of the trans-
membrane sequence (Fig. 3). The 3´ LTR drives the expression of a
truncated 2.3 kb mRNA that includes the coding sequences for the
transmembrane domain and the intracellular portion of Notch4.
Removal of extracellular domain regulatory sequences, such as the
LIN12 domain, is predicted to give rise to active forms of Notch4.
It is not clear whether such polypeptides associate transiently with
membranes (and thus require presenilin for activation), or are 
constitutively nuclear.
The int-3/Notch4 oncoprotein transforms epithelial cells in a
variety of murine assays. Enforced expression of int-3/Notch4 in
cultured mammary epithelial cells induces anchorage-independent
growth, matrix invasion and loss of contact inhibition.63,66 In vivo,
an MMTV-int-3/Notch4 transgene causes abnormal proliferation
and partial maturation arrest of mammary epithelium, followed by
development of frank adenocarcinoma.67 Abnormal growth of
epithelia also occurs in other tissues where the MMTV promoter is
active, such as salivary glands and epididymis, indicating that effects
of int-3/Notch4 are not strictly restricted to the mammary gland.67
The potential of int-3/Notch4 to induce malignant transformation
in other cellular compartments has not been reported, and down-
stream mechanisms of transformation are largely unknown.
The Notch1 gene has also been identified as a site of MMTV
proviral insertion in murine mammary carcinomas. MMTV infection
was used to screen for insertion sites that accelerated tumorigenesis
caused by the Erb2 transgene.68 Of 24 tumors analyzed, two had
proviral insertions within the Notch1 gene that are predicted to give
rise to aberrant transcripts encoding constitutively active forms of
Notch1.
In contrast to the animal models, information on Notch in
human breast cancer is scarce and indirect.69,70 Notch4 mRNA is
expressed in selected human breast cancer cell lines.69 Interestingly,
Northern blot analyses have detected the presence of a truncated 1.8
kb Notch4 transcript in two breast cancer, one colon carcinoma, and
two lung carcinoma cell lines. This transcript contains only 3´ 
coding sequences and is predicted to encode a truncated intracellular
polypeptide consisting of much of the intracellular portion of
Notch4. The relevance of these findings remains to be studied. The
expression of other Notch family members in breast cancer has not
been documented. 
NOTCH AND LUNG CANCER 
Notch has also been linked to the pathogenesis of small-cell lung
cancer (SCLC), a tumor with neuroendocrine (NE) differentiation.
In contrast to the previous examples of T cell leukemia and
MMTV-induced breast cancer, there is good evidence development
of SCLC involves the up-regulation of a specific pathway normally
antagonized by Notch signaling.71,72
Similar to T cell development and leukemia, Notch signaling is
involved in both normal pulmonary development and tumorigenesis.
During human fetal development, pulmonary neuroendocrine cells
(PNEC) selectively express a highly conserved bHLH protein,
Achaete-scute homologue-1 (ASH-1), which is required for the NE
features of these cells.71,73,74 During this process, Notch signaling
controls pulmonary epithelial cell fate by activating HES, which in
turn suppresses genes required for NE cell differentiation, such as
ASH1.74 In experimental models of the developing lung, ASH1 is
expressed in PNEC, while Notch1 and HES1 are strongly expressed in
non-PNEC.71,74 ASH1 forms a heterodimer with other ubiquitously
expressed bHLH factors, and drives the expression of downstream
genes needed for neuronal or NE differentiation.73,74 Both HES1
and HES3 bind the hASH1 promoter and repress hASH1 transcrip-
tion,75,76 providing one mechanism for downregulation of ASH1 by
Notch. ICN1 may also induce hASH1 degradation through
TAD-dependent polyubiquitination of the hASH1 protein.77
Mice lacking ASH1 have no detectable PNEC, while forced
expression of ASH1 results in lung hyperplasia and metaplasia,
though these cells displayed no detectable NE markers.71,74,78 This
suggests that while necessary, ASH1 is not sufficient for pulmonary
NE differentiation. In contrast, enforced expression of both ASH1
and SV40 Large T Antigen results in aggressive lung adenocarcinomas
with NE features, a phenotype previously found only in spontaneous
murine tumors.78 Of interest, the targets of Large T antigen, p53
and Rb, are frequently inactivated in human lung cancers.79
Human ASH1 is highly expressed in many SCLC lines,80 but it
is not detectable in non-SCLC (NSCLC) cell lines.80,81 hASH1
transcripts are also highly over-expressed (1000-fold) in primary
SCLC tumors, as compared to non-SCLC tumors and normal
bronchial biopsies.82 Experimentally, over-expression of ICN1 or
ICN2 in two human SCLC cell lines caused marked growth 
suppression stemming from a G1 cell cycle arrest
72 accompanied by
up-regulation of the cyclin-dependent kinase inhibitors (CDKI)
p21Cip1 and p27Kip1. Overexpression of HES1 only partially
arrests cell growth, suggesting other Notch1 targets are involved as
well. 
NOTCH AND NEUROBLASTOMAS 
In addition to NE cell differentiation, ASH1 is also crucial for
neuronal tissue determination.83-85 As in NE cells, Notch antagonizes
ASH1 in the developing sympathetic nervous system. In experimental
models, ICN1 over-expression inhibits the development of various
neuronal-derived cells in wildtype, HES1-/-, and HES5-/- cells, but
not in the HES1/HES5-double null background, suggesting both
HES proteins can suppress neuronal determination.86 In addition,
HES1 deficient mice exhibit premature neuronal differentiation and
increased ASH1 expression.87 The involvement of ASH1 in the
development of the nervous system and NE cells, as well as in
SCLC, led to an examination of its expression in neuroblastoma
(NB), a highly aggressive childhood tumor. Similar to SCLC, NB cells
exhibit high expression of ASH1 and low to absent expression of HES
family proteins.81,85,88 However, the direct link between ASH1 and
the tumor phenotype is less clear than in SCLC. 
Current clinical trials are based upon the efficacy of agents such
as retinoic acid (RA) or phorbol esters in the growth arrest and 
differentiation of NB cell lines in vitro.89 Using the same cell culture
systems, several groups found transduction of NB cell lines by either
ICN1 or HES1 blocks drug-induced differentiation. This effect 
contrasts with the ICN1-induced growth arrest seen in SCLC cells.88
However, one caveat concerns the complexity of effects mediated by
RA treatment. Numerous RA-responsive genes are members of the
DEC/STRA/SHARP (DSS) family of bHLH family of proteins.13,90
DSS proteins closely resemble HES proteins, but lack the C-terminal
WRPW motif that recruits members of the Groucho/TLE family 
of transcriptional corepressors. It is therefore possible HES proteins
antagonize the function of DSS proteins, thereby negating the 
RA signal to differentiate. Additional work is required to understand
the effect of Notch in both normal neural development and trans-
formation.
Another tumor of likely neuroectodermal origin is Ewing’s sarcoma,
which usually presents in childhood. Most Ewing’s sarcomas have
translocations involving members of the EWS gene family, which
undoubtedly play a central role in the pathogenesis of this neoplasm.
In addition, manic fringe (MFNG) is reportedly expressed at high
levels in Ewing’s sarcoma cells.91 In an experimental model, overex-
pression of MNFG renders fibroblasts tumorigenic in SCID mice.
The relevance of this finding to the pathogenesis of Ewing’s sarcoma
awaits further studies. 
NOTCH AND SKIN CANCER 
Notch receptors are reported to be downregulated in basal cell
carcinoma.92 In addition, mounting experimental data supports a
role for Notch in regulating cell differentiation and growth arrest at
the boundary between the basal layer cluster of progenitor cells and
the adjacent cells.18,93 Whether Notch down-regulation has a role 
in the pathogenesis of certain types of human skin cancer remains
speculative. 
The human skin contains clusters of highly proliferative undif-
ferentiated cells in the basal cell layer (for review, see ref. 94) capable
of self-renewal as well as differentiation.95,96 In model mammal
organisms, a “bulge” stem cell with capacity to differentiate into hair
follicles and epidermis has been identified, but whether the human
basal stem cell clusters retain the ability to form hair follicles remains
unknown (for review, see ref. 97).98,99 The basal layer of the cutaneous
interfollicular epithelium rests on the basement membrane and gives
rise to stratified suprabasal layers of increasingly differentiated cells:
the relatively undifferentiated stratum spinosum; the stratum granu-
losum layer, defined by the presence of keratin granules; and a stratum
corneum layer comprised of flattened, fused cell remnants consisting
mostly of keratin.100 All four Notch receptors are expressed in
regions of the basal and suprabasal layers, but in different patterns,
suggesting distinct functional roles. In human adult and fetal skin
samples, Notch1 protein and mRNA are expressed in all layers of the
epidermis, but at the highest levels in the stratum spinosum.93,101
Notch2 protein is distributed only in the basal cell layer, while
expression at the basement membrane is limited to Notch3. Both
Notch3 and Notch4 protein are coexpressed in the suprabasal layers.101
The expression patterns of Notch ligands and Fringe family 
modulators add additional layers to this complexity. Transcripts for
Delta-like 1 (Dll-1), Jagged 1, and all three known mammalian
Fringes are found in the basal cell layer of the interfollicular epider-
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mis.92,93,101 Interestingly, one group found clustered expression of
Dll-1 in the basal cell layer near the dermal papillae, the regions of
the dermis that project upward and interdigitate with the epidermal
(rete) ridges,93 and reported that this group of cells is resistant to
ICN1-induced differentiation.100 It seems likely that the complex
expression patterns of various Notch receptors, ligands and Fringe
modulators create other “microniches” within the epidermis that 
differ with respect to Notch signaling tone, and more generally
reflect a requirement for very tight spatiotemporal control of Notch
signaling in the skin.
Altered Notch expression patterns have been reported in basal
cell carcinoma (BCC), as well as cutaneous disorders characterized
by hyperproliferation, such as psoriasis and wound healing.92
Though controversial, most data suggest BCC originate from the
basal layer of the outer root sheath of the hair follicle,71,102-104 which
closely resembles the interfollicular basal layer of the epidermis in
terms of surface molecule expression patterns, including
Notch.101,105 In comparison to normal basal cells, BCCs show lower
levels of Notch1, Notch2, Dll-1, Jagged1 and all three Fringe
mRNA transcripts.92 To date, no other skin malignancies have been
reported with abnormal Notch expression patterns.
Experimental mouse models also suggest that Notch drives 
differentiation and growth arrest in keratinocytes.18 Conditional
ablation of Notch1 in the basal cell layer under the control of the
keratin-5 promoter results in epidermal hyperplasia and loss of 
differentiation. In addition, presenilin1 (PS1) deficient mice develop
spontaneous skin cancers.106 Unlike Notch1 knockout mice, many
of the signaling abnormalities in these mice stem from Notch-inde-
pendent increases in β-catenin stabilization, through loss of negative
inhibitory effects of PS1 on Wnt signaling. β-catenin stabilization in
turn up-regulates cyclin D1 induction through the transcription 
factor LEF,106 eventually leading to accelerated G1 progression.
Possibly, decreased Notch signaling and hyperactive Wnt signaling
may synergize to drive skin tumor development in this model 
system. Of interest, complex interactions between the Notch and Wnt
pathways play crucial roles in normal Drosophila wing development
and segmentation (reviewed in refs. 107, 108). Other signaling
pathways, like the Ras pathway, have also been postulated to interact
with Notch signals in human fibroblast and epithelial transformed
cell lines, however, these data remain speculative and need further
analysis.109
NOTCH IN CERVICAL CANCER 
The Notch pathway has also been implicated in cervical cancer.
Multiple reports show elevated Notch expression in cervical carcinoma
cells.110-113 However, recent data suggests that Notch1 is downreg-
ulated in late-stage HPV-infected tumors, and that Notch signals
counteract the HPV-induced transformation,113 indicating the 
relationship of Notch signaling to cervical carcinogenesis is complex.
Normally, a squamous epithelium covers the ectocervix and a
columnar epithelium covers the endocervical canal. The basal 
portion of the endocervical epithelium also contains a reserve cell
precursor population that can undergo either squamous or columnar
cell differentiation.114,115 In normal squamous ectocervix, only the
stratum spinosum layer has detectable Notch receptors, whereas in
normal columnar endocervix Notch1 and Notch2 are present on
reserve cells.110,111 Human Jagged1 and Dll-1 have an identical 
pattern of expression as Notch receptors in both endocervix and
ectocervix, whereas Jagged2 has not been detected. 
The definitive stem cell precursor(s) for each endocervical and
ectocervical layer remains to be identified. However, basal epithelial
cells at the endocervical-ectocervical junction are prone to metaplastic
transformation, and stain strongly with Notch1, Notch2, Jagged1
and Delta1 antibodies.110,111 While this suggests that Notch may
function to regulate cellular fate decisions at the cervical squamo-
columnar junction, the responsible signals and receptors, as well as
the identity of the critical target cells, are unclear. Notch signaling
may provide a permissive environment for development of early
pre-cancerous lesions. Notch 1 and Notch 2 expression levels are
high in cervical squamous carcinoma in situ and early dysplastic
HPV-induced lesions (CIN I-III).110-112 Jagged1, Jagged2 and
Delta1 display similar expression patterns in metaplastic epithelia.
Progression from CIN III to carcinoma was reported by one group
to be associated with decreased surface and cytoplasmic Notch1
staining, and increased nuclear staining.25 However, other data point
in the opposite direction. Most notably, Dotto’s group recently
grouped cervical tumors according to the presence of episomal HPV
DNA and the histology of the lesion of origin. Notch1 proteins were
readily detected in lysates from HPV-negative cervical carcinoma
cells and HPV-positive cell lines derived from low-grade cervical
lesions, but HPV-positive high-grade cervical lesions had sharply
reduced Notch1 protein levels.113 Interestingly, Notch2 protein
expression did not vary, while Notch3 and Notch4 proteins were
undetectable. Normal cervical tissue surrounding the lesions 
displayed Notch1 and Notch2 protein expression, in agreement with
previously published data. 
The net effect of Notch1 signaling may be suppression of
HPV-dependent activities. ICN1, but not ICN2, antagonizes the
HPV-URR promoter, which regulates E6 and E7 activity, in a
CSL-independent manner.113 This occurs through down-regulation
of c-Fos and upregulation of Fra1, two AP-1 family members, the
net effect of which is to favor the formation of inhibitory AP-1 
complexes composed of Jun-Fra heterodimers.116 The resulting
restricted expression of oncoproteins E6 and E7 is hypothesized to
antagonize late stages of tumor progression. An additional provocative
finding is that E6 binds human MAML1.9 Perhaps this serves to
inhibit MAML1 activity, thus limiting Notch signaling and 
promoting progression of late stage cervical neoplasms. Less certain
is an explanation for how Notch signaling might promote the devel-
opment of early stage cervical neoplasms. 
NOTCH IN OTHER EPITHELIAL TUMORS 
Notch receptor expression has been characterized in experimental
models of prostate tumors, though the number of studies is limited.
In addition, the Notch pathway is clearly involved in the organo-
genesis of other tissues like the pancreas, but currently there are no
reports linking Notch signals or expression to the etiology of other
carcinomas.117,118 
NOTCH AND PROSTATE CANCER 
The role of Notch in human prostate cancer has not been examined
directly. However, a murine model of prostate tumor formation 
suggests that Notch signals can inhibit prostate cancer progression.
Notch1 expression during murine prostate development was examined
using a Notch1 promoter transgene driving GFP expression as a 
surrogate marker. Expression is localized to the basal epithelial layer
of the prostate during fetal development, but is down-regulated in
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the adult.119 In contrast, expression is elevated in prostate tumors
induced by SV40 large T antigen,120 but whether this correlates with
increased Notch1 signaling is unknown. In contrast, enforced
expression of ICN1 inhibits the growth of various prostate cancer
cell lines119; however, the relevance of phenotypes produced by high
levels of ICN1 is unclear. Although these experiments suggest Notch
may regulate growth and development of normal and malignant
prostate cells, additional work is required to determine if these findings
are relevant to primary human prostate cancer.
INTEGRATED VIRAL PROTEIN PATHWAYS AND NOTCH 
Additional insight into the molecular mechanisms through which
Notch contributes to transformation came from the study of oncogenic
viruses. A diverse group of viral oncoproteins target the Notch pathway,
emphasizing its importance in normal cellular regulation of growth
and/or differentiation. We have previously discussed the complex
interplay between HPV and Notch in the pathogenesis of cervical
cancer. We now turn our attention to two oncogenic herpes viruses.
The two predominant types of human herpesviruses associated
with human malignancies are Epstein Barr virus (EBV or HHV4)
and Kaposi’s sarcoma-associated herpesvirus (KSHV or HHV8).
Most humans are latently infected with the EBV. Except for cases of
infectious mononucleosis, the acute infection is usually asympto-
matic, but the virus persists in latent form. If such individuals suffer
from acquired deficits of T cell immunity, this small pool of cells can
undergo rapid expansion, giving rise to EBV-associated B cell 
lymphoproliferative disorders.121 The other herpesvirus, KSHV, also
causes several tumors that occur predominantly in immunosuppressed
individuals: Kaposi’s sarcoma, a tumor of endothelial origin122,123;
and an unusual B cell lymphoma that arises in effusions.124
The main reservoir for latent EBV and KSHV infection is the B
lymphocyte.121,125-127 Expression of KSHV RTA is necessary for the
switch from viral latency to lytic reactivation, while EBV EBNA-2
helps maintain latency.128-130 Interestingly, multiple proteins necessary
for cellular transformation by EBV and KSHV, including EBNA2
and RTA, bind CSL.130-133 RTA binding results in Notch-inde-
pendent transcriptional activation of CSL targets, which promotes
G1 arrest and eventually triggers lytic reactivation.
130 EBNA-2 is
involved in the up-regulation of proteins that contribute to latency
(for review, see ref. 134). EBNA-3a and EBNA-3c, in contrast,
inhibit CSL-dependent transcription, suggesting that EBV latency
(and probably B cell transformation) requires tight regulation of
CSL activity.135 The region of CSL that binds RTA and EBNA-2 is
identical130,132,136 which may have complex consequences in B cell
lymphomas that are co-infected with EBV and KSHV. 
The human population is also widely infected with adenovirus
type 5. One of its early genes, E1A, has been widely used as a model
oncogene in rodent cell lines.137 Despite this, adenoviruses have not
been linked to human tumors, and E1A induces human tumor cell
lines to adopt a more mature epithelial phenotype.138-140 The activity
of E1A as a tumor suppressor or differentiation agent has not yet
been mapped. Intriguingly, the 13S-E1A adenoviral oncoprotein
binds and activates CSL, similar to EBNA-2 and RTA.141 Like
EBNA-3, another adenoviral protein, 12S-E1A, represses CSL-
dependent transcription.142 Understanding the physiological effects
of these proteins will require additional studies in naturally infected
host cells. 
DISCUSSION 
The three general mechanisms of tumorigenesis that involve the
Notch pathway are summarized in Table 1. Various translocations
and proviral insertions in Notch receptor genes lead to ligand-
independent production of ICN-like polypeptides. Such events
underlie Notch-associated T-ALLs in humans, felines, and mice, and
murine mammary carcinomas. In developing T cells, enforced
expression of ICN1-3 results in a maturation arrest at the
CD4+CD8+ DP stage that likely contributes to oncogenesis. The
second mechanism involves ligand-mediated Notch receptor activa-
tion. This mechanism has been demonstrated in experimental models,
but its importance in sporadic cancers is unclear. Finally, a diverse
group of tumors seem to be associated with dampening of Notch 
signals through generally uncertain mechanisms. The clearest 
evidence supporting a role for Notch as a tumor suppressor comes
from HPV-driven cervical carcinomas, in which Notch1 downregu-
lation appears to be important during late stages of tumor progression.
The complex and occasionally paradoxical effects of Notch 
signals on cellular transformation are reflections of the protean
effects of this signaling pathway on normally developing tissues and
cells. The Notch pathway controls numerous developmental cell fate
decisions through the regulation of genes involved in differentiation
and proliferation. Notch receptors, ligands, and other signaling 
components have dynamic overlapping patterns of expression, 
suggesting that this pathway is subject to extensive fine-tuning to
ensure that the timing and strength of Notch signals is appropriate
for context. Cancers commonly resemble cells corresponding to 
normal stages of development, and it is thus not surprising that
Notch signaling molecules are widely expressed in diverse neoplasms. A
major challenge for the field is to distinguish stage-appropriate
expression of Notch signaling components from aberrant expression
that is pathophysiologic. This is not trivial, since tumors may 
recapitulate stages of normal tissue development that occur early in
development, or have as their origin rare cells that are difficult to
study. The frequent targeting of Notch signaling components by
viral oncogenes provides strong presumptive evidence of a general
role in cellular transformation. However, clear evidence of a broader
Table 1 POTENTIAL ROLES OF NOTCH SIGNALING IN HUMAN
CANCERS
Mechanisms of Potential Tumor Potential Therapies
Tumor Progpagation Examples
Gain of function T-ALL, mouse Intracellular inhibitors
mutations mammary of the NOTCH
carcinomas pathway (disrupt ICN
nuclear complex,
activate Notch 
inhibitors
Ligand-mediated Lymphoproliferative Intracellular or
activation of the disorders (CLL, extracellular inhibitors
Notch pathway Hodgkin’s lymphoma) of the Notch pathway
(block ligand-Notch
binding or same
targets as above).
Downregulation of SCLC, prostate Activate the Notch
the Notch pathway adenocarcinomas, pathway (soluble
cervical carcinomas, ligands, antibody 
basal cell cancer, activation of Notch
neuroblastomas signaling).
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role in sporadic human tumors awaits detection of additional
acquired mutations or epigenetic modifications in Notch signaling
components that alter function. Development of specific modifiers
of Notch signals will also improve our ability to assess their role in
particular tumor types.
The current trend in cancer therapy is to replace systemic
chemotherapy with target-specific biologicals/chemicals, such as
all-trans retinoic acid and imatinib mesylate (STI571). Because Notch
is widely expressed and affects many differentiation processes, toxicities
associated with targeting of this pathway may be unacceptable,
although this remains to be seen. If true, it may be possible to focus on
the downstream mediators of Notch signaling, rather than components
of the central signaling axis. Ideas for potential targets are presented
in Table 1. 
In summary, Notch signaling is likely involved in the pathogenesis
of a variety of human tumors. As in differentiation, its effect is 
probably context-specific, inhibiting transformation in some tissues
and promoting malignancy in others. An improved understanding
of Notch signaling in normal development and malignant transfor-
mation may lead to novel cancer therapeutics. 
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